Abstract: The present invention provides methods for the treatment of cancers by administration of inhibitors of the PI3K-AKT-mTORCl pathway (or components downstream of this pathway such as SREBP and SCD1) and agents that induce ferroptosis to subjects in need thereof. The present invention also provides various related compositions and related methods.

Abstract: The present technology is directed to compounds, compositions, and methods related to inhibition of ULK1 and treatment of cancers therefrom.

Abstract: The present disclosure relates generally to methods for determining whether a patient diagnosed with cancer will benefit from or is predicted to be responsive to treatment with a ferroptosis-inducing therapy. These methods are based on screening a cancer patient for mutations in cadherin and/or the Merlin-Hippo-YAP signaling pathway.

Abstract: A layered, microfluidic array is disclosed. The array has a first layer with a culture channels extending in a first longitudinal direction. Each culture channel includes multiple traps that entrap cell or tissue samples. The array also has a second layer with microfluidic channels extending in a second longitudinal direction that is orthogonal the first longitudinal direction. A third layer, disposed between the first layer and the second layer, has pores arranged within the third layer such that each nest is vertically stacked above, and fluidly connected with, a corresponding culture chamber in the first layer. Each nest is fluidly isolated from adjacent nests by a fluid impermeable region of the third layer such that horizontal diffusion of water within the third layer is prevented.

Abstract: A layered, microfluidic array is disclosed. The array has a first layer with a culture channels extending in a first longitudinal direction. Each culture channel includes multiple traps that entrap cell or tissue samples. The array also has a second layer with microfluidic channels extending in a second longitudinal direction that is orthogonal the first longitudinal direction. A third layer, disposed between the first layer and the second layer, has pores arranged within the third layer such that each nest is vertically stacked above, and fluidly connected with, a corresponding culture chamber in the first layer. Each nest is fluidly isolated from adjacent nests by a fluid impermeable region of the third layer such that horizontal diffusion of water within the third layer is prevented.

Abstract: A layered, microfluidic living cell array is disclosed. The cell array comprises a first layer comprising at least one cell culture channel; a second layer comprising at least one microfluidic channel; and a third layer, disposed between the first layer and the second layer. The third layer comprises a filter membrane with a plurality of pores, each pore fluidly connecting the microfluidic channel to the cell culture channel.

Abstract: The present invention is directed to ferroptosis and glutaminolysis inhibitors and to methods of treatment or prevention of an organ injury caused by ischemia-reperfusion in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a ferroptosis inhibitor or a glutaminolysis inhibitor.

Abstract: A layered, microfluidic array is disclosed. The array comprises a first layer comprising at least one culture channel; a second layer comprising at least one microfluidic channel; and a third layer, disposed between the first layer and the second layer. The third layer comprises a filter membrane with a plurality of pores, each pore fluidly connecting the microfluidic channel to the culture channel.

Abstract: Bacillus Calmette-Guerin (BCG) administration plays a central role in managing carcinoma in situ of the bladder. Unfortunately, recurrence or progression of disease is seen in up to 30% of treated patients. Disclosed herein is a method for predicting responsiveness to treatment with BCG based on BCG internalization by bladder cancer cells, the presence or absence of mutations associated with BCG uptake or a combination thereof.

Abstract: A layered, microfluidic living cell array is disclosed. The cell array comprises a first layer comprising at least one cell culture channel; a second layer comprising at least one microfluidic channel; and a third layer, disposed between the first layer and the second layer. The third layer comprises a filter membrane with a plurality of pores, each pore fluidly connecting the microfluidic channel to the cell culture channel.

Abstract: The subject invention relates to a novel small molecule, referred to as alpha-(trichloromethyl)-4-Pyridineethanol (PETCM), as well as to uses thereof. PETCM was identified and isolated by high throughput screening and is an activator of caspase-3. Using PETCM in combination with biochemical fractionation, a novel pathway that regulates mitochondria-initiated caspase activation was also identified. This pathway comprises tumor suppressor PHAP proteins and oncoprotein prothymosin-alpha. PETCM relieves prothymosin-alpha inhibition and allows apoptosome to form at a physiological concentration of dATP.